Biomarkers /
FLT1
Overview
Fms-related tyrosine kinase 1 (FLT1) is a gene that encodes a protein that is a receptor tyrosine kinase in the vascular endothelial growth factor receptor (VEGF) family. Missense mutations, nonsense mutations, silent mutations, and frameshift deletions are observed in cancers such as intestinal cancer, skin cancer, and stomach cancer.
FLT1 is altered in 3.07% of all cancers with lung adenocarcinoma, colon adenocarcinoma, cutaneous melanoma, melanoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in FLT1 are FLT1 Mutation (2.48%), FLT1 Missense (2.35%), FLT1 Amplification (0.39%), FLT1 Nonsense (0.17%), and FLT1 Loss (0.08%) [3].
Clinical Trials
Significance of FLT1 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.